CardiologyHyperlipidemias

Oral PCSK9 Inhibitors: Opening Cardiovascular Prevention to Millions

If approved, an oral PCSK9 inhibitor could reach 10x more patients than injectables ever did

SR-2026-015

EditorMara Voss

CopywritersEditorial Team

Coming Soon

Oral PCSK9 Inhibitors: Opening Cardiovascular Prevention to Millions

If approved, an oral PCSK9 inhibitor could reach 10x more patients than injectables ever did

Why We Are Covering This

Injectable PCSK9 inhibitors proved their LDL-lowering efficacy but reached only a fraction of eligible patients. An oral formulation in late-stage development changes both the clinical and commercial math in cardiovascular prevention.

What to Expect

You will leave knowing how oral PCSK9 inhibition compares to statins and ezetimibe on efficacy and cost, how payers are likely to position an oral agent, and what approval would mean for the cardiovascular prevention market.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-01507/26

Heart Failure

Universal Heart Failure Definition Issued by Global Societies

Four major cardiology societies released a universal definition of heart failure, aiming to standardise diagnosis and research across the globe.

Coronary Artery Disease

Novel Therapies Target Atherogenic Lp(a) Particle

Emerging therapeutic strategies are shifting focus from LDL cholesterol to apoB, targeting Lp(a) and other atherogenic particles.

Coronary Artery Disease

Vitamin K2 Supplementation May Curb Coronary Calcification

Evidence suggests vitamin K2 supplementation may reduce coronary artery calcification, a key marker of cardiovascular disease risk.

Aortic Valve Stenosis

AI-Assisted Fetal Echocardiography Improves Early CHD Detection

Artificial intelligence (AI) integration into fetal echocardiography improves early detection of congenital heart disease (CHD), including aortic stenosis.

Oral PCSK9 Inhibitors: Opening Cardiovascular Prevention to Millions

Oral PCSK9 Inhibitors: Opening Cardiovascular Prevention to Millions

Be first when this report publishes

Related Articles